top of page


an unmet need

Osteoarthritis (OA), a degenerative joint disease characterized by progressive articular cartilage loss and intermittent inflammation, is among the most frequently diagnosed diseases and a leading cause of disability in the western world. However, perhaps surprisingly, despite these trends, there are no drugs available (yet) that can halt or reverse the process, with palliative care or surgery frequently being the only options available. The development of effective drugs has been hampered by the lack of experimental models that can adequately mimic the disease.



Pregenerate’ s Optimate OA™ is a game-changing technology that accurately and reliably mimics the joint environment by combining novel microfluidic engineering (capillary- and shear force driven) principles, 3D cell cultivation methods and geometric design constraints of the microchambers to drive native-like cellular behaviour.

Changing the Game

Pregenerate’s Cartilage-on-a-chip® based test allows to evaluate individual response profile to osteoarthritis treatments, analysing expression of genes representative of inflammation, regeneration and degeneration. Thus evaluating how the patient' cells would react to treatment prior to administration, empowering physicians and patients in making appropriate, informed treatment selection.

Misty Slope


for microscopy imaging and gene expression profiling

Recent studies (Hall A. C. (2019)) have identified early changes to human chondrocyte morphology and volume occurring before marked cartilage degeneration and loss. Our understanding of early stages of tissue failure can be aided by modern data science tools including machine learning approaches that can provide stratified clinical decision support.

bottom of page